PRLD Graph | PRELUDE THERAPEUTICS INC

PRLD Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $5.70M; Research and development $16.13M; Operating expenses $21.16M; Net income -$13.92M.
2026-03-31: Revenue $4.58M; Research and development $13.60M; Operating expenses $18.76M; Net income -$10.38M.
2025-12-31: Revenue $5.64M*; Research and development $17.99M*; Operating expenses $22.99M*; Net income -$16.46M*.
2025-09-30: Revenue $6.50M; Research and development $21.71M; Operating expenses $26.92M; Net income -$19.73M.

Type Of Arrangement

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$5.70M	$16.13M	$21.16M	-$13.92M
2026-03-31	$4.58M	$13.60M	$18.76M	-$10.38M
2025-12-31	$5.64M*	$17.99M*	$22.99M*	-$16.46M*
2025-09-30	$6.50M	$21.71M	$26.92M	-$19.73M
2025-06-30	$0.00	$25.78M	$32.19M	-$31.23M
2025-03-31	$0.00	$28.82M	$34.61M	-$32.09M
2024-09-30	$3.00M	$29.46M	$37.38M	-$32.27M
2024-06-30	(m)	$29.51M	$37.16M	-$34.74M
2024-03-31	(m)	$27.41M	$34.34M	-$31.43M
2023-09-30	(m)	$26.26M	$33.38M	-$30.61M
2023-06-30	(m)	$24.97M	$32.40M	-$30.43M
2023-03-31	(m)	$21.83M	$29.11M	-$27.72M
2022-09-30	(m)	$22.89M	$30.41M	-$29.96M
2022-06-30	(m)	$21.31M	$29.46M	-$27.37M
2022-03-31	(m)	$22.82M	$30.29M	-$29.46M
2021-09-30	(m)	$22.72M	$30.84M	-$30.69M
2021-06-30	(m)	$22.41M	$27.92M	-$26.86M
2021-03-31	(m)	$16.47M	$21.97M	-$21.30M
2020-09-30	(m)	$15.29M	$18.14M	-$16.76M
2020-06-30	(m)	$9.78M	$11.44M	-$11.41M
2020-03-31	(m)	$8.54M	$9.74M	-$9.51M
2019-09-30	(m)	$5.49M	$6.88M	-$6.73M
2019-06-30	(m)	(m)	(m)	-$5.56M
2019-03-31	(m)	(m)	(m)	-$5.24M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$10.28M	$29.73M	$39.91M	-$24.31M
2025-06-30	$0.00	$54.60M	$66.80M	-$63.32M
2024-06-30	(m)	$56.92M	$71.51M	-$66.17M
2023-06-30	(m)	$46.80M	$61.51M	-$58.15M
2022-06-30	(m)	$44.13M	$59.75M	-$56.84M
2021-06-30	(m)	$38.88M	$49.89M	-$48.16M
2020-06-30	(m)	$18.31M	$21.17M	-$20.92M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Net income
2025-09-30	$6.50M	$76.31M	$93.72M	-$83.04M
2024-09-30	$3.00M	$86.38M	$108.88M	-$98.44M
2023-09-30	(m)	$73.06M	$94.90M	-$88.76M
2022-09-30	(m)	$67.02M	$90.16M	-$86.80M
2021-09-30	(m)	$61.60M	$80.72M	-$78.85M
2020-09-30	(m)	$33.60M	$39.32M	-$37.68M
2019-09-30	(m)	$15.43M	$18.01M	-$17.53M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$12.14M	$94.30M	$116.71M	$0.00	-$99.50M
2024-12-31	$7.00M	$118.00M	$146.71M	$0.00	-$127.17M
2023-12-31	(m)	$103.39M	$132.28M	(m)	-$121.83M
2022-12-31	(m)	$92.89M	$123.54M	(m)	-$115.44M
2021-12-31	(m)	$86.78M	$113.73M	(m)	-$111.69M
2020-12-31	(m)	$48.18M	$58.76M	(m)	-$56.93M
2019-12-31	(m)	$24.28M	$28.11M	(m)	-$27.57M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Evommune, Inc. (EVMN)	United States	$0.320B	-5.10
BridgeBio Oncology Therapeutics, Inc. (BBOT)	United States	$0.320B	-3.35
ABEONA THERAPEUTICS INC. (ABEO)	United States	$0.312B	-5.63
GT Biopharma, Inc. (GTBP)	United States	$0.309B	-4.58
BioAge Labs, Inc. (BIOA)	United States	$0.333B	-11.88
Vanda Pharmaceuticals Inc. (VNDA)	United States	$0.302B	-1.35
Benitec Biopharma Inc. (BNTC)	United States	$0.337B	-10.08
STANDARD BIOTOOLS INC. (LAB)	United States	$0.297B	3.80
ROCKET PHARMACEUTICALS, INC. (RCKT)	United States	$0.296B	-21.78
Larimar Therapeutics, Inc. (LRMR)	United States	$0.344B	-1.83